NASDAQ:MYGN - Myriad Genetics Stock Price, Forecast & News

Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."

Myriad Genetics, Inc. (NASDAQ:MYGN) released its earnings results on Thursday, February, 6th. The company reported $0.23 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.22 by $0.01. The firm earned $195.10 million during the quarter, compared to analysts' expectations of $209.61 million. Myriad Genetics had a positive return on equity of 5.42% and a negative net margin of 3.22%. Myriad Genetics's revenue for the quarter was down 10.0% on a year-over-year basis. During the same period in the previous year, the firm posted $0.38 EPS. View Myriad Genetics' Earnings History.

Myriad Genetics is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Myriad Genetics.

Myriad Genetics issued an update on its FY20 earnings guidance on Thursday, February, 6th. The company provided earnings per share (EPS) guidance of approx $0.45 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.02. The company issued revenue guidance of approx $735 million, compared to the consensus revenue estimate of $807.66 million.

8 brokerages have issued 12 month target prices for Myriad Genetics' stock. Their forecasts range from $17.00 to $36.00. On average, they anticipate Myriad Genetics' share price to reach $25.63 in the next twelve months. This suggests a possible upside of 30.4% from the stock's current price. View Analyst Price Targets for Myriad Genetics.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last year. There are currently 3 sell ratings, 4 hold ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Myriad Genetics.

News articles about MYGN stock have trended somewhat positive this week, according to InfoTrie. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Myriad Genetics earned a news sentiment score of 1.6 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Myriad Genetics.

Myriad Genetics saw a decrease in short interest during the month of January. As of January 31st, there was short interest totalling 12,820,000 shares, a decrease of 6.2% from the January 15th total of 13,670,000 shares. Based on an average trading volume of 1,025,600 shares, the short-interest ratio is currently 12.5 days. Currently, 17.8% of the shares of the company are sold short. View Myriad Genetics' Current Options Chain.

Some companies that are related to Myriad Genetics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Myriad Genetics investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alibaba Group (BABA), Kratos Defense & Security Solutions (KTOS), STMicroelectronics (STM) and Gilead Sciences (GILD).

Myriad Genetics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (12.05%), State Street Corp (5.22%), Earnest Partners LLC (4.84%), Geode Capital Management LLC (1.41%), Bank of New York Mellon Corp (1.25%) and New York State Common Retirement Fund (1.23%). Company insiders that own Myriad Genetics stock include Bernard Tobin, Dennis Langer, Gary A King, Jerry S Lanchbury, John T Henderson, Mark Christopher Capone, Nicole Lambert, Ralph L Mcdade, Richard Bryan Riggsbee, Richard M Marsh and Walter Phd Gilbert. View Institutional Ownership Trends for Myriad Genetics.

MYGN stock was sold by a variety of institutional investors in the last quarter, including Rice Hall James & Associates LLC, Baillie Gifford & Co., Royce & Associates LP, Man Group plc, Point72 Asset Management L.P., Russell Investments Group Ltd., AQR Capital Management LLC and Bank of New York Mellon Corp. Company insiders that have sold Myriad Genetics company stock in the last year include Bernard Tobin, Gary A King, Nicole Lambert, Ralph L Mcdade and Richard Bryan Riggsbee. View Insider Buying and Selling for Myriad Genetics.

MYGN stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Global Alpha Capital Management Ltd., Earnest Partners LLC, FMR LLC, Renaissance Technologies LLC, Great West Life Assurance Co. Can, Credit Suisse AG and Stifel Financial Corp. Company insiders that have bought Myriad Genetics stock in the last two years include John T Henderson and Walter Phd Gilbert. View Insider Buying and Selling for Myriad Genetics.

Shares of MYGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MYGN stock can currently be purchased for approximately $19.65.

Myriad Genetics has a market capitalization of $1.46 billion and generates $851.10 million in revenue each year. The company earns $4.60 million in net income (profit) each year or $1.29 on an earnings per share basis. Myriad Genetics employs 2,600 workers across the globe.View Additional Information About Myriad Genetics.

The official website for Myriad Genetics is http://www.myriad.com/.

Myriad Genetics' mailing address is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. The company can be reached via phone at 801-584-3600 or via email at [email protected]